摘要
目的:评价阿立哌唑治疗精神分裂症的临床疗效与安全性。方法:对我院187例精神分裂症患者随机临床对照研究,分别给予阿立哌唑和盐酸氯丙嗪治疗8周,采用PANSS和TESS评定临床疗效和不良反应。结果:试验结束时两组疗效相似,阿立哌唑组起效时间早于氯丙嗪组;且在治疗阴性症状方面,以阿立哌唑显著较好。阿立哌唑组不良反应较盐酸氯丙嗪组少。结论:阿立哌唑是一种安全有效、见效快、不良反应轻的治疗精神分裂症的药物。
Objective：To detect the clinical efficacy and side effect of aripiprazole in the treatment of schizophrenia. Methads： 187 Schizophrenia patients have been divided into aripiprazole group and chlorpromazine group randomly for 8 weeks. PANSS, TESS were used to evaluate the efficacy and side effects respectively. Results： The efficacy of both drugs were same, aripiprazole had a more rapid onset of action and less side effects than chlorpromazine. But significant difference were found between two groups in the reduction rate of scale about negative symptoms. Patients in aripiprazole group recorded much fewer side effects than those in chlorpromazine group. Conclusions： Aripiprazole is a safe and effective drug for schizophrenia patients with more rapid onset of action.
出处
《中国民康医学》
2007年第17期715-716,共2页
Medical Journal of Chinese People’s Health
